Nektar Therapeutics

Nektar Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing immunotherapy medicines for autoimmune disease and cancer. Its pipeline centers on proprietary immunomodulatory drug candidates such as rezpegaldesleukin, NKTR-255 and NKTR-0165, while much of its historical revenue came from collaborations, royalties and licensing arrangements rather than marketed products.

−251,8 %

100,0 %

−297,1 %

−43,9 %

4.97

4.97

— Nektar Therapeutics
%
Clinical-stage immunotherapy pipeline15% Drug candidates in autoimmune disease and cancer that are being advanced through preclinical and clinical development.
Collaboration and licensing revenue45% Upfront fees, milestones and other contingent payments from pharma and biotech partners.
Royalty income20% Non-cash and cash royalty streams tied to partnered products developed using Nektar technology.
Manufacturing and supply agreements10% Historical product sales from fixed-price manufacturing and supply arrangements with collaborators.
Intellectual property and platform technology10% PEGylation and polymer conjugate technologies licensed to partners for drug development and commercialization.

Nektar’s direct customers are primarily pharmaceutical and biotechnology collaboration partners that license its...

  • Pharmaceutical collaboration partnersprimary

    Large and mid-sized pharma companies that license Nektar’s assets or technology and pay milestones, royalties or supply fees.

  • Biotechnology development partnersprimary

    Biotech companies that co-develop or in-license immunology assets and use Nektar’s platform to advance candidates.

  • Clinical trial ecosystemsecondary

    Hospitals, investigators and CROs that support patient enrollment, clinical operations and regulatory development.

  • Future prescribers and patientsemerging

    Physicians and patients in autoimmune disease and oncology who would use approved products if programs succeed.

Nektar is headquartered in the United States and its business is tied to U.S. clinical development, regulatory...

  • •Headquartered in the United States
  • •Clinical development and regulatory work centered in the U.S.
  • •Partnered products have had U.S. and European commercialization
  • •No current marketed product base of its own
  • •Historical manufacturing revenue ended after facility sale in 2024

Nektar is prioritizing advancement of its internal immunotherapy pipeline, especially rezpegaldesleukin, while seeking...

01
Advance rezpegaldesleukin in autoimmune diseaseshort-term

It is the lead asset and the main driver of future value creation and partnering interest.

02
Secure new collaboration agreementsshort-term

The company lost collaboration-based revenue after the Eli Lilly termination and needs external funding support.

03
Progress the broader immunotherapy pipelinemedium-term

Multiple shots on goal reduce dependence on a single asset and improve long-term partnering value.

04
Conserve capital and simplify operationsshort-term

As a clinical-stage company without marketed products, liquidity and burn management are critical.

Nektar’s value is highly dependent on clinical success, especially for rezpegaldesleukin, and failure in trials would...

critical

Clinical failure of rezpegaldesleukin

The company states future success is highly dependent on this lead asset, and most investigational drugs fail before approval.

Scope
Autoimmune disease pipeline
Materiality
high
high

Loss of collaboration revenue

Termination of the Eli Lilly collaboration means no collaboration-based revenue for key drug candidates unless new deals are signed.

Scope
Rezpegaldesleukin, NKTR-255, NKTR-0165, NKTR-0166
Materiality
high
high

Liquidity and financing risk

The company relies on cash, equity financing and partner funding to support R&D until commercialization or new partnerships.

Scope
Operating runway and clinical funding
Materiality
high
high

Regulatory approval risk

Drug development requires lengthy FDA and global review, and approval is not assured even after positive data.

Scope
All pipeline assets
Materiality
high
medium

Competitive intensity

Larger pharma and biotech companies may have superior resources, faster development programs and stronger commercialization capabilities.

Scope
Autoimmune and oncology immunotherapy
Materiality
medium
medium

Manufacturing and quality risk

Contract manufacturers must produce biologics at required quality and scale to support trials and future supply.

Scope
Clinical supply chain
Materiality
medium
ASC 606 collaboration revenue recognition
Affects license, collaboration and other revenue
Non-cash royalty revenue and non-cash interest expense
Can distort earnings versus operating cash generation
Asset impairment and lease accounting
Can materially affect operating results and balance sheet values
Collaborative arrangement presentation
Changes gross revenue and expense presentation

Egetis Therapeutics

EGTX.ST · Health Care

UNITED THERAPEUTICS Corp

UTHR · Pharmaceutical Preparations

Nkarta, Inc.

NKTX · Pharmaceutical Preparations

Neuronetics, Inc.

STIM · Surgical & Medical Instruments & Apparatus

Akari Therapeutics Plc

AKTX · Pharmaceutical Preparations

APTARGROUP, INC.

ATR · Plastics Products, NEC

: 28.4.2026